The report discloses that the company has recognized and sought to mitigate a range of operational disruptions—“losing key molecules and intermediaries or our compound library through a natural or man-made disaster or act of sabotage could negatively impact the product development cycle,” manufacturing shutdowns or product shortages arising from failures to comply with cGMP, and “disruption in supply chain continuity including from natural disasters, acts of war or terrorism or other external factors over which we have no control impacting one of our facilities or at a critical supplier.” It further acknowledges that “a significant breakdown, invasion, corruption, destruction or interruption of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations,” and notes ongoing investments in “industry appropriate protections and monitoring practices of our data and IT to reduce these risks and continue to monitor our systems on an ongoing basis for any current or potential threats,” while admitting “there can be no assurance … that our efforts will prevent breakdowns or breaches.” To bolster strategic and operational flexibility, the company “announced an evolution to our operating model to drive the company’s continued success in the near- and long-term through a more focused investment in commercial opportunities for key brands and markets, a competitive and more agile R&D organization that can accelerate the pipeline, streamlined operations and realigned manufacturing capabilities that broaden biologics capabilities to reflect the current and future portfolio,” and anticipates restructuring actions “to deliver the strategic, financial and operational flexibility necessary to invest in the highest priorities.” To manage inventory-related risks and comply with its SEC consent order, it “has established a company-wide policy to limit our sales to direct customers … includes the adoption of various procedures to monitor and limit sales … governance process to escalate to appropriate management levels potential questions or concerns regarding compliance with the policy,” and utilizes “inventory management agreements” with wholesalers providing weekly information on months-on-hand. Liquidity and funding resilience are supported by “existing cash, cash equivalents and marketable securities together with cash generated from operations and issuance of commercial paper,” as well as two separate $1.5 billion revolving credit facilities with no financial covenants, extendable to 2020 and 2021, “sufficient to satisfy our normal cash requirements for at least the next few years.”